Search
Besifloxacin
go.drugbank.com/drugs/DB06771ApprovedBesifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsChenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalChenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPhenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of butyric acid naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPhloretin
go.drugbank.com/drugs/DB07810ExperimentalPhloretin is a natural dihydrochalcone found in apples and many other fruits.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A Inhibitors(R)-warfarin
go.drugbank.com/drugs/DB08496ExperimentalWarfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesBupranolol
go.drugbank.com/drugs/DB08808ExperimentalBupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesPerampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalPerampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersRegorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBedaquiline
go.drugbank.com/drugs/DB08903ApprovedInvestigationalBedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial acti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigationalTrametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers